ProCE Banner Activity

Phase I Trial of Patritumab Deruxtecan for Previously Treated Advanced NSCLC Without EGFR Activating Mutations

Slideset Download
Conference Coverage
Results from a phase I trial showed that patritumab deruxtecan was active in heavily pretreated patients with unresectable locally advanced or metastatic NSCLC without EGFR activating mutations.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab